Several studies have demonstrated overexpression of mesothelin (a glycoprotein present on mesothelial cells lining the pleura, peritoneum, and pericardium) in most epithelial ovarian cancers and have suggested the eligibility of mesothelin as a target for cancer therapy [47, 48]. This evidence concerns the gene MSLN and ovarian carcinoma.